

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of treatment for mastalgia, comprising administering 4-hydroxy tamoxifen percutaneously to the breasts of a patient having mastalgia, at a dose of at least 1.5 mg/day.
2. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is in a vehicle containing a penetration enhancer.
3. (Currently Amended) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a racemic blend of *trans* and *cis* isomers.
4. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a *trans* isomer.
- Claim 5 (Canceled)
6. (Original) A method according to claim 1, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
7. (Original) A method according to claim 1, wherein greater than about 1 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
8. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic gel.
9. (Original) A method according to claim 8, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
10. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in an alcoholic solution.

11. (Original) A method according to claim 1, wherein said mastalgia is cyclical.
12. (Previously Presented) A method according to claim 1, wherein about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
13. (Previously Presented) A method according to claim 1, wherein about 1 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
14. (Previously Presented) A method according to claim 1, wherein about 2 mg of said 4-hydroxy tamoxifen is administered to said patient per day.